Ptc Therapeutics, Inc.
A biopharmaceutical company that develops treatments for rare diseases, with medicines including Sephience for PKU, Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy, and the gene therapy Upstaza/Kebilidi. Founded in 1998 by RNA researcher Stuart Peltz, the company's name comes from "post-transcriptional control," the field of RNA biology it was built around.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 13G/APassive | 8.7% | 7.19M | May 15, 2026 |
| The Toronto-Dominion Bank | 13G/APassive | 3.7% | 3.03M | May 15, 2026 |
| Vanguard Capital Management | 13GPassive | 5.17% | 4.28M | Apr 30, 2026 |
| Vanguard Portfolio Management | 13GPassive | 5.88% | 4.87M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Wellington Management Group LLP | 13G/APassive | 4.8% | 3.87M | Feb 10, 2026 |
| Wellington Group Holdings LLP | 13G/APassive | 4.8% | 3.87M | Feb 10, 2026 |
| Wellington Investment Advisors Holdings LLP | 13G/APassive | 4.8% | 3.87M | Feb 10, 2026 |
| STATE STREET CORPORATION | 13GPassive | 5.2% | 4.21M | Feb 9, 2026 |
| BlackRock, Inc. | 13G/APassive | 14.8% | 11.90M | Dec 4, 2025 |